1. c‑Jun and FOXO1 mediate the expression of oncogenic PKC‑ι in human prostate cancer cells with an interplay between NF‑κB, IL‑8 and ICAM‑1
    WISHRAWANA RATNAYAKE et al, 2020, World Academy of Sciences Journal CrossRef
  2. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer
    Bishal Gyawali et al, 2016, Critical Reviews in Oncology/Hematology CrossRef
  3. Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer
    Takahiro Kirisawa et al, 2023, International Cancer Conference Journal CrossRef
  4. Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases
    Jian-zhou Cao et al, 2021, OncoTargets and Therapy CrossRef
  5. Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance
    Yaron Ilan et al, 2020, Cancer Treatment and Research Communications CrossRef
  6. Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
    André Mansinho et al, 2018, Molecular & Diagnostic Imaging in Prostate Cancer CrossRef
  7. Intermittent Chemotherapy with Docetaxel for Metastatic Castration-Resistant Prostate Cancer
    Shintaro Narita et al, 2018, Hormone Therapy and Castration Resistance of Prostate Cancer CrossRef
  8. Ability of intermittent androgen suppression to selectively create a non-trivial periodic orbit for a type of prostate cancer patients
    Yoshito Hirata et al, 2015, Journal of Theoretical Biology CrossRef
  9. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
    Ciara Conduit et al, 2022, Therapeutic Advances in Medical Oncology CrossRef
  10. Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer
    Satoru Taguchi et al, 2020, Japanese Journal of Clinical Oncology CrossRef